Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Second Line Treatment With Nal-IRI and S1 in Pancreatic Cancer (NAPAN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03986294
Recruitment Status : Recruiting
First Posted : June 14, 2019
Last Update Posted : July 2, 2019
Sponsor:
Collaborators:
UMC Utrecht
Isala
Maastricht University Medical Center
Vall de Hebron, Barcelona, Spain
University Hospital Verona, Italy
Odense University Hospital, Denmark
Medical University of Vienna
Information provided by (Responsible Party):
J.W. Wilmink, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Brief Summary:
To determine the optimal second line treatment strategy in patients with metastatic pancreatic cancer who underwent a therapy with gemcitabine.

Condition or disease Intervention/treatment Phase
Metastatic Pancreatic Cancer Drug: S1 + Nal-IRI Drug: Nal-IRI+Leucovorin+5-FU Phase 2

Detailed Description:

The 5-year survival of patients with pancreatic cancer is less than 5%. Despite improvements over the past years with the introduction of FOLFIRINOX (5-fluorouracil, irinotecan, oxaliplatin and leucovorin) and gemcitabine and nab-paclitaxel, the vast majority will have disease recurrence or progression within 6 months. Single-arm phase II studies have been conducted after gemcitabine-based therapy. Randomized clinical trial data are limited in this setting, but the conclusion up to recently was that there is no superior chemotherapeutic regimen after gemcitabine failure. However, the NAPOLI trial altered the treatment landscape. In this trial, patients with metastatic pancreatic cancer that progressed after treatment with gemcitabine-based chemotherapy received liposomal irinotecan (nal-IRI) either as single agent or in combination with 5-fluorouracil/ leucovorin (5-FU/LV), or 5-FU/LV alone. Patients treated with the combination of nal-IRI plus 5-FU/LV experienced a median survival of 6.1 months versus 4.2 months for the 5-FU/LV group.

Recently, two studies on the clinical use of S-1 for pancreatic cancer have been reported from Japan. In the first study, S-1 demonstrated non-inferiority to gemcitabine in overall survival (OS) for advanced pancreatic cancer. In the second study, S-1 showed superiority to adjuvant chemotherapy with gemcitabine in OS. In addition to gemcitabine, S-1 is now regarded as the key drug in the management of pancreatic cancer in Japan. Phase II studies of S-1 in patients with gemcitabine-resistant pancreatic cancer have demonstrated moderate activity with acceptable toxicity. Although there has been no confirmed evidence based on phase III trials, S-1 would be a feasible treatment option in this patient population.

Objective:

To determine the optimal second line treatment strategy in patients with metastatic pancreatic cancer, whereby the hypothesis is, based on studies conducted in the Asian population, that the combination of S-1 and nal-IRI will be superior compared to 5-FU/ LV and nal-IRI, in terms of progression free survival. Therefore, patients will be randomized, after the optimal dose of S-1 and nal-IRI has been determined in the run in phase, between S-1 in combination with nal-IRI and 5-FU/LV in combination with nal-IRI during the phase II part of the study.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 122 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
Official Title: A Randomized Phase II Study of Second Line Treatment With Liposomal Irinotecan and S1 Versus Liposomal Irinotecan and 5-fluorouracil in Patients With Metastatic Pancreatic Cancer Who Failed on First Line Gemcitabine-based Chemotherapy
Estimated Study Start Date : July 1, 2019
Estimated Primary Completion Date : January 1, 2022
Estimated Study Completion Date : January 1, 2022


Arm Intervention/treatment
Experimental: S1 and liposomal irinotecan
S-1 will be given for 14 consecutive days, twice daily, followed by 2 weeks rest. Nal-IRI will be administered as an iv infusion on day 1 and 15. Treatment will be repeated every 4 wks.
Drug: S1 + Nal-IRI
S-1 will be given for 14 consecutive days, twice daily, followed by 2 weeks rest. Nal-IRI will be administered as an intravenous infusion on day 1 and 15. Courses of treatment will be repeated every 4 weeks.

Drug: Nal-IRI+Leucovorin+5-FU
Nal-IRI 80 mg/m2 will be administered first, followed by LV 400 mg/m2, followed by 5-FU 2400 mg/m2 as an IV infusion over 46-hours on days 1-3. Each cycle consists of 14 days. Courses of treatment will be repeated every 2 weeks.

Experimental: Liposomal irinotecan, Leucovorin and 5-fluoracil
Nal-IRI 80 mg/m2 administered first, followed by LV 400 mg/m2, followed by 5-FU 2400 mg/m2 as an IV infusion over 46-hrs on days 1-3. Each cycle consists of 14 days. Treatment will be repeated every 2 wks.
Drug: Nal-IRI+Leucovorin+5-FU
Nal-IRI 80 mg/m2 will be administered first, followed by LV 400 mg/m2, followed by 5-FU 2400 mg/m2 as an IV infusion over 46-hours on days 1-3. Each cycle consists of 14 days. Courses of treatment will be repeated every 2 weeks.




Primary Outcome Measures :
  1. DLT of Nal-IRI with S1 [ Time Frame: 36 months ]
    Dose limiting toxicity (DLT) of nal-IRI when co-administered with fixed dose S1 in patients with metastatic pancreatic cancer

  2. MTD of Nal-IRI with S1 [ Time Frame: 36 months ]
    Maximum tolerated dose (MTD) of nal-IRI when co-administered with fixed dose S1 in patients with metastatic pancreatic cancer

  3. Progression free survival of NaI-IRI with S1 [ Time Frame: 36 months ]
    Determination of the efficacy between the treatment arms in terms of progression free survival.


Secondary Outcome Measures :
  1. Overall survival [ Time Frame: 36 months ]
    To determine the overall survival (OS) benefit of nal-IRI combined with S-1, compared with nal-IRI combined with 5-FU/LV, in subjects pre-treated with gemcitabine based chemotherapy for metastatic pancreatic ductal adenocarcinoma.

  2. Response rate according to RECIST 1.1 [ Time Frame: 36 months ]
    To determine the response rate according to RECIST 1.1 of nal-IRI combined with S-1, compared with nal-IRI combined with 5-FU/LV, in subjects pre-treated with gemcitabine based chemotherapy for metastatic pancreatic ductal adenocarcinoma.

  3. Adverse events according NCI CTC version 4.0 [ Time Frame: 36 months ]
    To determine the adverse events according to NCI CTC version 4.0 of nal-IRI combined with S-1, compared with nal-IRI combined with 5-FU/LV, in subjects pre-treated with gemcitabine based chemotherapy for metastatic pancreatic ductal adenocarcinoma.

  4. Quality of life QoL (QLQ-C30) [ Time Frame: 36 months ]
    To determine Quality of life (QoL) benefit of nal-IRI combined with S-1, compared with nal-IRI combined with 5-FU/LV, in subjects pre-treated with gemcitabine based chemotherapy for metastatic pancreatic ductal adenocarcinoma using a questionnaire QLQ-C30.Scale ranges 1-4, 1 is very good, 4 is very bad. Higher values represent a worse outcome.


Other Outcome Measures:
  1. stromal markers [ Time Frame: 36 months ]
    To assess expression of relative abundance of stroma in metastatic tumor tissue and stromal markers, including ADAM12 in metastatic tumor tissue and blood as predictor of response to treatment and survival.

  2. Imaging (MRI) [ Time Frame: 36 months ]
    To explore, by imaging the number of participants with the effects of the treatment combination on tumor vascularity, and stromal density.

  3. ctDNA [ Time Frame: 36 months ]
    To explore the number of participants with changes in ctDNA.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Subjects must satisfy all of the following inclusion criteria to be enrolled in the study.

  1. Able to understand and provide written informed consent
  2. ≥ 18 years of age
  3. Histologically or cytologically confirmed adenocarcinoma of pancreas
  4. Documented metastatic disease, according to RECIST 1.1.
  5. Previously treated with gemcitabine or gemcitabine containing therapy, or progression within 6 months of adjuvant gemcitabine based treatment
  6. Adequate hepatic, renal and hematological function

Exclusion Criteria:

A potential subject who meets any of the following criteria will be excluded from participation in this study:

  1. Serum total bilirubin ≥1.5 x ULN (biliary drainage is allowed for biliary obstruction)
  2. Severe renal impairment (CLcr ≤ 30 ml/min)
  3. Inadequate bone marrow reserves as evidenced by:

    1. ANC ≤ 1,5 x 10 9 /L; or
    2. Platelet count ≤ 100 x 10 9 /L;
  4. WHO/PS 0-1
  5. Any clinically significant disorder impacting the risk-benefit balance negatively per physician's judgment
  6. Any clinically significant gastrointestinal disorder, including hepatic disorders, bleeding, inflammation, occlusion, or diarrhea > grade 1
  7. Severe arterial thromboembolic events (myocardial infarction, unstable angina pectoris, stroke) in last 6 months
  8. NYHA Class III or IV congestive heart failure, ventricular arrhythmias or uncontrolled blood pressure. Or known abnormal ECG with clinically significant abnormal findings
  9. Active infection or an unexplained fever >38.5°C (excluding tumor fever), which in the physician's opinion might compromise the patient's health
  10. Current use or any use in last two weeks of strong CYP3A-enzyme inducers/inhibitors and/or strong UGT1A inhibitors
  11. Known hypersensitivity to any of the components of liposomal irinotecan (Nal-IRI) other liposomal irinotecan formulations, irinotecan, fluoropyrimidines, or leucovorin.
  12. Hypersensitivity to any of the active substances (tegafur, gimeracil, and oteracil)
  13. Previous treatment with fluoropyrimidine therapy
  14. Known dihydropyrimidine dehydrogenase (DPD) deficiency
  15. Breast feeding, known pregnancy, positive serum pregnancy test or unwillingness to use a reliable method of birth control, during therapy and for 3 months following the last dose of liposomal irinotecan (Nal-IRI).

Treatment within 4 weeks with DPD inhibitors, including sorivudine or its chemically related analogues such as brivudine.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03986294


Contacts
Layout table for location contacts
Contact: J W Wilmink, MD, PhD 31 20 5665955 j.w.wilmink@amsterdamumc.nl
Contact: E. N. Pijnappel, M.D. 31 20 5665955 e.n.pijnappel@amsterdamumc.nl

Locations
Layout table for location information
Netherlands
Academic Medical Center, Medical Oncology Recruiting
Amsterdam, Netherlands, 1100 DD
Contact: J. W. Wilmink, MD, PhD, PhD    31 20 5665955    j.w.wilmink@amsterdamumc.nl   
Contact: Lyda ter Hofstede    31 20 5668229    trialmedonc@amc.uva.nl   
Principal Investigator: H. WM van Laarhoven, MD, PhD, PhD         
Principal Investigator: J. W. Wilmink, M.D., Ph.D.         
Sponsors and Collaborators
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
UMC Utrecht
Isala
Maastricht University Medical Center
Vall de Hebron, Barcelona, Spain
University Hospital Verona, Italy
Odense University Hospital, Denmark
Medical University of Vienna
Investigators
Layout table for investigator information
Principal Investigator: J W Wilmink, MD, PhD Ademic Medical Center Amsterdam

Layout table for additonal information
Responsible Party: J.W. Wilmink, Principle investigator, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
ClinicalTrials.gov Identifier: NCT03986294     History of Changes
Other Study ID Numbers: NL64126.018.17
First Posted: June 14, 2019    Key Record Dates
Last Update Posted: July 2, 2019
Last Verified: June 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by J.W. Wilmink, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA):
Liposomal irinotecan
S1
Pancreatic cancer
Second line

Additional relevant MeSH terms:
Layout table for MeSH terms
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Irinotecan
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents